Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Vandana Abramson

Professor of Medicine

University Name

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

70%

Immunology

20%

Oncology

60%

Targeted Therapy

40%

Cancer Therapy

30%

Hormone Therapy

20%

Tumor Immunology

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles18

Multiplex Spatial Proteomic Analysis of HER2–Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response

Article Link

Year:

2025

Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer

Article Link

Year:

2024

Prospective surveillance with compression for subclinical lymphedema

Article Link

Year:

2023

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer

Article Link

Year:

2023

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.

Article Link

Year:

2023

NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer

Article Link

Year:

2023

Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).

Article Link

Year:

2023

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.

Article Link

Year:

2023

Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.

Article Link

Year:

2023

Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospective Clinical Trial.

Article Link

Year:

2023

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.

Article Link

Year:

2023

A comparison of bioimpedance spectroscopy or tape measure triggered compression intervention in chronic breast cancer lymphedema prevention

Article Link

Year:

2022

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

Article Link

Year:

2022

Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.

Article Link

Year:

2022

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.

Article Link

Year:

2022

A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC).

Article Link

Year:

2021

Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).

Article Link

Year:

2021

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.

Article Link

Year:

2021

Collaborators11

Sheila Ridner

Vanderbilt University School of Nursing

UNITED STATES

Jodi Carter

Associate Professor

University of Alberta

CANADA

Justin M. Balko

Vanderbilt University Medical Center

UNITED STATES

Samarpan Majumder

Louisiana State University Health Sciences Center

UNITED STATES

Louise Koelmeyer

Macquarie University

AUSTRALIA

Katrina Gaitatzis

Macquarie University

AUSTRALIA

Thomas Hughes

Associate Professor

Australian National University

AUSTRALIA

Andrew Tutt

Institute of Cancer Research

UNITED KINGDOM

John Boyages

Macquarie University

AUSTRALIA

Quanhu Sheng

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES

Jiun-Ruey Hu

Yale University

UNITED STATES

How do I reach out?

Meet Kite AI